Cardiff Oncology (CRDF) Reports Q3 Loss, Tops Revenue Estimates

Cardiff Oncology (CRDF) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.22 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 7.41%. A quarter ago, it was expected that this molecular diagnostic company would post a loss of $0.25 per share when it actually produced a loss of $0.26, delivering a surprise of -4%.Over the last four quarters, the co ...